<DOC>
	<DOCNO>NCT01422265</DOCNO>
	<brief_summary>This multicenter , observational , prospective study include approximately 20 US-based center , approximately 142 patient diagnosed epithelial ovarian cancer , primary peritoneal carcinoma fallopian tube carcinoma , whose disease recur &gt; 6 month first-line platinum-based chemotherapy ( first recurrence ) . Patients complete second-line chemotherapy currently observation undergo bevacizumab maintenance treatment eligible participate study .</brief_summary>
	<brief_title>Patient Reported Symptoms Ovarian Cancer ( PRECISION )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Histologically documented ovarian cancer , primary peritoneal carcinoma fallopian tube carcinoma recur &gt; 6 month platinumbased chemotherapy This must first recurrence epithelial ovarian cancer , primary peritoneal carcinoma fallopian tube carcinoma Are least two week 3 month completion secondline cytotoxic chemotherapy Are currently observation treat bevacizumab secondline maintenance therapy Have valid email address access internet Provide voluntary write informed consent Speak read English fluently Current participation blind clinical trial ovarian cancer treatment . ( Participation trial involve supportive care medicine and/or growth factor acceptable ) Another primary diagnosis cancer different site</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>